Arrowsmith
Vancouver, Canada · Founded 2021
- Headquarters
- Vancouver
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
About
Arrowsmith Genetics Inc. is a preclinical-stage precision oncology company that reverse-engineers the drug development process to identify novel cancer therapeutic targets using a genetics-driven platform. Co-founded in 2021 by Peter Stirling (CEO), Nigel O'Neil (CSO), and Phil Hieter at the University of British Columbia, the company develops advanced cell-based drug models that reduce the risk and cost of early-stage cancer drug discovery — addressing the high failure rate of conventional target identification tools. Arrowsmith Genetics won the 2022 Amgen/SBME Golden Ticket award, advanced to the Top 25 of the NVBC Competition, and was selected as a UBC spin-off in 2024/2025, with an ambition to expand its pipeline of drug candidates across multiple tumor types for pharma partnerships.
Summary
Arrowsmith is a Biotech company based in Vancouver, Canada, founded in 2021.
Similar Companies
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
Biotechnology company using AI to learn from life's chemistry and discover medicines 4X faster.
Biopharmaceutical company pioneering Helicon peptide drugs to target previously undruggable prote...